

## CLAIMS

1. A cranial nerve disease therapeutic agent for *in vivo* administration, comprising a mesenchymal cell as an active ingredient.
- 5 2. The agent of claim 1, wherein the cranial nerve disease is cerebral infarction.
3. An agent for *in vivo* administration, exhibiting neuroprotection and comprising a mesenchymal cell as an active ingredient.
4. An agent for *in vivo* administration, exhibiting cranial nerve regeneration and comprising a mesenchymal cell as an active ingredient.
- 10 5. The agent of any one of claims 1 to 4, wherein the *in vivo* administration is intravenous.
6. The agent of any one of claims 1 to 5, wherein the mesenchymal cell is:
  - (a) a mesenchymal cell introduced with a BDNF gene, PLGF gene, GDNF gene, or IL-2 gene;
  - or
  - (b) an immortalized mesenchymal cell introduced with an hTERT gene.
- 15 7. The agent of any one of claims 1 to 6, wherein the mesenchymal cell is a mesenchymal stem cell.
8. The agent of any one of claims 1 to 6, wherein the mesenchymal cell is a bone marrow cell, a cord blood cell, or a peripheral blood cell.
9. A method for treating a cranial nerve disease comprising the *in vivo* administration to a
- 20 patient of a therapeutically effective amount of the agent of any one of claims 1 to 8.
10. The method of claim 9, wherein the bone marrow cell is an autologous cell of the patient.
11. The method of claim 9 or 10, wherein the cranial nerve disease is cerebral infarction.
12. The method of any one of claims 9 to 11, wherein the *in vivo* administration is intravenous administration.
- 25 13. The method of any one of claims 9 to 12, wherein the mesenchymal cell is a bone marrow cell, a cord blood cell, or a peripheral blood cell.